Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;9(4):R45.
doi: 10.1186/bcr1747.

Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer

Azita Monazzam  1 , Raymond Josephsson, Carl Blomqvist, Jörgen Carlsson, Bengt Långström, Mats Bergström
Affiliations

Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer

Azita Monazzam et al. Breast Cancer Res. 2007.

Abstract

Introduction: Positron emission tomography (PET) is suggested for early monitoring of treatment response, assuming that effective anticancer treatment induces metabolic changes that precede morphology alterations and changes in growth. The aim of this study was to introduce multicellular tumour spheroids (MTS) to study the effect of anticancer drugs and suggest an appropriate PET tracer for further studies.

Methods: MTS of the breast cancer cell line MCF7 were exposed to doxorubicin, paclitaxel, docetaxel, tamoxifen or imatinib for 7 days for growth pattern studies and for 3 or 5 days for PET tracer studies. The effect on growth was computed using the semi-automated size determination method (SASDM). The effect on the uptake of PET tracers [18F]3'-deoxy-3'-fluorothymidine (FLT), [1-11C]acetate (ACE), [11C]choline (CHO), [11C]methionine (MET), and 2-[18F]fluoro-2-deoxyglucose (FDG) was calculated in form of uptake/viable volume of the MTS at the end of the drug exposures, and finally the uptake was related to effects on growth rate.

Results: The drugs paclitaxel, docetaxel and doxorubicin gave severe growth inhibition, which correlated well with inhibition of the FLT uptake. FLT had, compared with ACE, CHO, MET and FDG, higher sensitivity in monitoring the therapy effects.

Conclusion: SASDM provides an effective, user-friendly, time-saving and accurate method to record the growth pattern of the MTS, and also to calculate the effect of the drug on PET tracer uptake. This study demonstrate the use of MTS and SASDM in combination with PET tracers as a promising approach to probe and select PET tracer for treatment monitoring of anticancer drugs and that can hopefully be applied for optimisation in breast cancer treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation between growth inhibition and tracer-uptake reduction after 3 days of treatment (1 and 10 μM).
Figure 2
Figure 2
The dose effect of treatment with docetaxel and doxorubicin recorded with FLT.
Figure 3
Figure 3
Ki67 staining of spheroid sections illustrating proliferating cells (black colour) after 3-day exposure to 1 μM non-drug medium (a), paclitaxel (b), docetaxel (c), doxorubicin (d), tamoxifen (e) and imatinib (f).
See this image and copyright information in PMC

References

    1. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003;44:224–239. - PubMed
    1. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer. 2002;38:375–379. doi: 10.1016/S0959-8049(01)00379-3. - DOI - PubMed
    1. Cohade C, Wahl RL. PET scanning and measuring the impact of treatment. Cancer J. 2002;8:119–134. - PubMed
    1. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol. 2005;23:1664–1673. doi: 10.1200/JCO.2005.11.024. - DOI - PubMed
    1. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–5372. doi: 10.1200/JCO.2006.05.7406. - DOI - PubMed

Publication types

MeSH terms